From the Front Lines

LEF News is reprinting a businesswire article on Elixir Pharmaceuticals. This company has picked up very rapidly on recent progeria (a rapid aging syndrom) genetic research. They are jumping right in to see how this knowledge can be used to fight normal aging. It's great to see this sort of thing happening: this is exactly why we need more young, enthusiastic, funded companies in the aging research space. Success breeds further success, so we wish Elixir the best of luck in their work.



Post a comment; thoughtful, considered opinions are valued. Comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.

Note that there is a comment feed for those who like to keep up with conversations.